Glenmark Pharmaceuticals Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹2235.50
Market cap
5 Cr
Stock P/E
0.0
P/B
0.00
Dividend yield
3014.5%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,402 Cr | 6,243 Cr | 8,750 Cr | 11,813 Cr | 3,244 Cr | 6,678 Cr | 3,388 Cr | 3,256 Cr | 3,264 Cr | 6,047 Cr | 3,901 Cr | 3,771 Cr |
| Operating expenses (approx.) | 2,802 Cr | 5,700 Cr | 8,446 Cr | 10,679 Cr | 2,624 Cr | 5,417 Cr | 2,756 Cr | 3,056 Cr | 2,981 Cr | 4,872 Cr | 3,171 Cr | 3,192 Cr |
| EBITDA | 600 Cr | 544 Cr | 304 Cr | 1,134 Cr | 620 Cr | 1,261 Cr | 631 Cr | 200 Cr | 284 Cr | 1,175 Cr | 730 Cr | 578 Cr |
| OPM % | 17.6% | 8.7% | 3.5% | 9.6% | 19.1% | 18.9% | 18.6% | 6.1% | 8.7% | 19.4% | 18.7% | 15.3% |
| Other income | 21 Cr | 21 Cr | 67 Cr | 840 Cr | 31 Cr | 71 Cr | 31 Cr | 12 Cr | 26 Cr | 201 Cr | 44 Cr | 189 Cr |
| Interest | 112 Cr | 233 Cr | 367 Cr | 516 Cr | 40 Cr | 88 Cr | 52 Cr | 67 Cr | 58 Cr | 66 Cr | 41 Cr | 43 Cr |
| Depreciation | 155 Cr | 283 Cr | 431 Cr | 582 Cr | 118 Cr | 238 Cr | 123 Cr | 125 Cr | 130 Cr | 141 Cr | 154 Cr | 148 Cr |
| Profit before tax | 333 Cr | 27 Cr | -494 Cr | 36 Cr | 462 Cr | 935 Cr | 456 Cr | 8 Cr | 96 Cr | 967 Cr | 534 Cr | 388 Cr |
| Tax % | 48.1% | 627.3% | -19.8% | 5116.7% | 26.4% | 25.7% | 23.7% | 45.0% | 50.9% | 36.9% | 24.5% | 22.3% |
| Net profit | 173 Cr | 110 Cr | -219 Cr | -1,434 Cr | 340 Cr | 695 Cr | 348 Cr | 4 Cr | 47 Cr | 610 Cr | 403 Cr | 301 Cr |
| EPS (₹) | ₹5.31 | ₹2.41 | ₹-10.04 | ₹-53.22 | ₹12.06 | ₹24.61 | ₹12.33 | ₹0.16 | ₹1.66 | ₹21.63 | ₹14.29 | ₹10.68 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 9,865 Cr | 10,641 Cr | 10,944 Cr | 12,305 Cr | 12,990 Cr | 11,813 Cr | 13,322 Cr | 16,983 Cr | Sign in for TTM |
| Operating expenses (approx.) | 7,904 Cr | 8,750 Cr | 8,765 Cr | 10,079 Cr | 11,478 Cr | 11,519 Cr | 11,229 Cr | 14,216 Cr | Sign in for TTM |
| EBITDA | 1,961 Cr | 1,891 Cr | 2,179 Cr | 2,226 Cr | 1,513 Cr | 294 Cr | 2,092 Cr | 2,767 Cr | Sign in for TTM |
| OPM % | 19.9% | 17.8% | 19.9% | 18.1% | 11.6% | 2.5% | 15.7% | 16.3% | Sign in for TTM |
| Other income | 208 Cr | 160 Cr | 50 Cr | 167 Cr | 317 Cr | 840 Cr | 114 Cr | 461 Cr | Sign in for TTM |
| Interest | 335 Cr | 377 Cr | 353 Cr | 298 Cr | 350 Cr | 516 Cr | 207 Cr | 209 Cr | Sign in for TTM |
| Depreciation | 326 Cr | 417 Cr | 444 Cr | 487 Cr | 611 Cr | 582 Cr | 486 Cr | 573 Cr | Sign in for TTM |
| Profit before tax | 1,301 Cr | 1,096 Cr | 1,382 Cr | 1,441 Cr | 868 Cr | 36 Cr | 1,399 Cr | 1,985 Cr | Sign in for TTM |
| Tax % | 28.9% | 29.2% | 29.8% | 31.1% | 56.5% | 5116.7% | 25.2% | 31.4% | Sign in for TTM |
| Net profit | 925 Cr | 776 Cr | 970 Cr | 994 Cr | 377 Cr | -1,434 Cr | 1,047 Cr | 1,362 Cr | Sign in for TTM |
| EPS (₹) | ₹32.78 | ₹27.50 | ₹34.38 | ₹33.37 | ₹10.53 | ₹-53.22 | ₹37.11 | ₹48.26 | Sign in for TTM |
| Dividend payout % | — | — | — | 9.3% | 36.2% | — | 6.7% | 10.4% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 28 Cr | 28 Cr | 28 Cr | 28 Cr | 28 Cr | 28 Cr | 28 Cr | 28 Cr |
| Reserves | 5,577 Cr | 6,042 Cr | 0.0000 Cr | 0.0000 Cr | 9,811 Cr | 7,820 Cr | 8,821 Cr | 10,484 Cr |
| Borrowings | 3,134 Cr | 3,574 Cr | 3,626 Cr | 3,670 Cr | 4,348 Cr | 991 Cr | 1,681 Cr | — |
| Other liabilities | 2,066 Cr | 2,152 Cr | 2,182 Cr | 2,506 Cr | 5,185 Cr | 5,520 Cr | 5,519 Cr | 9,396 Cr |
| Total liabilities | 17,143 Cr | 18,952 Cr | 20,618 Cr | 22,914 Cr | 19,372 Cr | 14,359 Cr | 16,050 Cr | 19,908 Cr |
| Fixed assets (net) | 1,308 Cr | 1,469 Cr | 1,490 Cr | 1,469 Cr | 3,904 Cr | 3,118 Cr | 3,319 Cr | 3,890 Cr |
| CWIP | 209 Cr | 152 Cr | 93 Cr | 101 Cr | 1,115 Cr | 419 Cr | 542 Cr | 428 Cr |
| Investments | 3,269 Cr | 4,714 Cr | 6,990 Cr | 8,559 Cr | 45 Cr | 790 Cr | 56 Cr | 42 Cr |
| Other assets | 5,141 Cr | 4,424 Cr | 4,909 Cr | 4,403 Cr | 9,874 Cr | 7,428 Cr | 9,295 Cr | 11,300 Cr |
| Total assets | 17,143 Cr | 18,952 Cr | 20,618 Cr | 22,914 Cr | 19,372 Cr | 14,359 Cr | 16,050 Cr | 19,908 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 1,109 Cr | 625 Cr | -265 Cr | -828 Cr | 3,445 Cr |
| Cash from investing | — | — | — | -333 Cr | -528 Cr | 4,369 Cr | 2 Cr | -1,283 Cr |
| Cash from financing | — | — | — | -520 Cr | -77 Cr | -3,906 Cr | 787 Cr | -2,709 Cr |
| Net cash flow | — | — | — | 272 Cr | 33 Cr | 215 Cr | 17 Cr | -501 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 319 Cr | 18 Cr | -1,164 Cr | -1,577 Cr | 2,087 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 29.2% | 24.3% | 6150.9% | 6164.2% | 6.4% | -3.3% | 15.3% | 20.9% |
| ROE % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -19.1% | 11.8% | 0.0% |
| Debtor days | 120 | 100 | 120 | 120 | 115 | 57 | — | — |
| Inventory days | 209 | 136 | 104 | 116 | 302 | 290 | 367 | 422 |
| Days payable | 383 | 257 | 221 | 236 | 242 | 293 | — | — |
| Cash conversion cycle | -53 | -21 | 3 | -0 | 174 | 55 | 367 | 422 |
| Debt / equity | 0.26 | 0.27 | 0.24 | 0.00 | 0.46 | 0.13 | 0.19 | — |
| Current ratio | 2.25 | 1.85 | 1.96 | 1.28 | 1.96 | 1.28 | 1.56 | 1.77 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 1.92 | -2.27 | 0.0028 | -0.42 |
Compare with peers
Loading peers…